Skip to main content Skip to main navigation menu Skip to site footer
Articles
Published: 2021-08-18

Laboratory manifestations of COVID-19 associated with hemostatic abnormalities

Department of Haematology, Faculty of Medical Laboratory Sciences, Sudan International University, Khartoum-Sudan
Department of Haematology and Immunohematology, College of Medical Laboratory Sciences, Sudan University of Science and Technology, Khartoum-Sudan
Pathology Department, Ibra Hospital, Ministry of Health – Oman.
COVID-19, Venous thromboembolism, D-Dimer, Thrombocytopenia, Fibrinogen Degradation Products, Oman, Sudan

Abstract

Hemostatic abnormalities had been reported in COVID-19 patients, which may include disseminated intravascular coagulation (DIC), hypercoagulability, and alterations in platelets parameters. Articles that investigate the alterations of hemostatic abnormalities during the COVID-19 disease (2020-2021) and their predictive value of disease outcome have been thoroughly reviewed. Among the reviewed articles, thrombocytopenia is observed in 5.0-41.7% of COVID-19 patients, which is related to disease severity. Moreover, other platelets parameters, including Platelets/lymphocytes ratio (PLR), Mean platelets volume (MPV), and aggregation, may also be affected. On the other hand, findings of coagulation tests such as D dimer; fibrinogen, Antithrombin (AT), and Fibrin degradation products (FDP) are significantly elevated in COVID-19 patients, while in a single study, most of the patients had positive Lupus anticoagulants (LA) and normal protein C (PC). In the same perspective, these alterations showed significant correlations with disease severity. Overall, hemostatic laboratory markers are significant predictors of COVID-19 disease outcome as indicated by the increased risk of venous and arterial thrombotic events, especially in ICU patients.

 



Downloads

Download data is not yet available.


How to Cite

1.
Elsadig AE, Ali MM, Yousif AA. Laboratory manifestations of COVID-19 associated with hemostatic abnormalities. jidhealth [Internet]. 2021 Aug. 18 [cited 2022 Aug. 15];4(3):423-7. Available from: https://www.jidhealth.com/index.php/jidhealth/article/view/133